Pharma stocks rose up to 4% as Novo Nordisk’s semaglutide patent nears expiry, raising expectations of cheaper generics in India. Strong growth potential in GLP-1 drugs, low penetration, and aggressive pricing by domestic players like Natco Pharma are driving investor interest in the sector.